Comprehensive Breast Health Center

China

Comprehensive Breast Health Center

China
SEARCH FILTERS
Time filter
Source Type

ALISO VIEJO, Calif., May 24, 2017 (GLOBE NEWSWIRE) -- Cianna Medical, Inc., the world leader in wire-free breast localization, announces that more than 125 medical centers across the U.S. have adopted the Company’s proprietary SCOUT® radar breast localization system.  SCOUT is the world’s only radar technology that has application in human tissue, and the system allows surgeons to precisely locate non-palpable breast lesions during a lumpectomy or biopsy surgery with ± 1mm of accuracy. Nationwide, community-based hospitals and leading academic cancer centers including USF Breast Health Program at the University of South Florida, Northwell Health, Houston Methodist Willowbrook Hospital and Houston Methodist The Woodlands Hospital have adopted this groundbreaking technology. “Our first priority is saving the lives of patients with cancer and, in the process, we strive to improve their radiological and surgical experiences,” said Anne M. Wallace, MD, director of the Comprehensive Breast Health Center at Moores Cancer Center at UC San Diego Health, the 100th hospital to adopt SCOUT. “With wire-free breast localization, there is a dual benefit. The surgeon can perform a more targeted operation that conserves healthy tissue while the patient experiences less discomfort and stress.” SCOUT is the world’s only non-radioactive, wire-free breast localization system. With SCOUT, the radiologist is able to place a tiny, highly sophisticated reflector at the tumor site with extreme precision. This can be done up to 30 days prior to surgery versus on the same day of surgery which is required with traditional wire localization. Instead of two procedures on the day of surgery, the patient now undergoes one, which can help make the experience significantly less stressful. During the procedure, the surgeon scans the breast using the SCOUT guide, which emits 50 million pulses per second, allowing the surgeon to “lock” in on the reflector’s precise location with ± 1mm of accuracy. This extraordinary accuracy can help surgeons provide the best possible outcomes. SCOUT has an exceptional detection range of 1mm – 50mm1, documented migration of only <1% across multiple studies1 and is 100% operating room (OR) compatible. “At Cianna Medical, we have been focused on breast conservation therapy for more than a decade. Our company is dedicated to helping reduce the anxiety and stress breast cancer treatments place on patients and their families. We do this by developing innovative technologies that improve the entire continuum of care,” said Jill Anderson, President and CEO of Cianna Medical. “Reaching adoption at more than 125 centers is a significant milestone and we are grateful for the uncompromising support of our clinical collaborators and dedicated team. We are confident that SCOUT is becoming the new standard of care and will be recognized as the breast localization technology of choice.” SCOUT was a recent category finalist in the 2016 Fierce Innovation Awards: Life Sciences Edition for outstanding technology innovation in December 2016. SCOUT also received the Scientific Impact Award at the 2016 Society of Breast Surgeons Annual Meeting for data validating its clinical utility. Earlier this year, SCOUT was also honored as a finalist in the 2017 Medical Design Excellence Awards. For more information, call 866.920.9444 or visit www.ciannamedical.com. About SCOUT® The FDA-cleared SCOUT system features a proprietary, highly sophisticated reflector that is precisely placed at the tumor site up to 30 days before a lumpectomy or surgical biopsy. During the procedure, the surgeon scans the breast using the SCOUT guide which emits 50 million pulses per second, allowing the surgeon to “lock” in on the reflector’s precise location with ± 1mm of accuracy. This higher level of localization precision allows better surgical planning that may improve cosmetic results as less tissue may need to be removed. SCOUT has an exceptional detection range of 1mm – 50mm, documented migration of <1% across multiple studies, and is OR compatible.i About Radar Technology The SCOUT system uses highly sophisticated radar technology. Radar is used when unprecedented precision is required. Applications using radar include ground penetrating radar, automobile safety systems, flight control systems and antimissile and air-defense systems. About Cianna Medical, Inc. Cianna Medical is the world leader in wire-free breast localization and has been focused on breast conservation for over 10 years. Cianna Medical develops, manufactures and markets innovative medical technologies that reduce costs, improve quality and reduce the anxiety and stress breast cancer treatments place on women and their families. Cianna Medical’s world class research, development and commercialization teams developed the world’s first non-radioactive, wire-free breast localization system and the world’s only technology that utilizes radar in tissue. Cianna Medical is focused on expanding applications that continually advance patient care. Its SCOUT and SAVI® Brachy technologies are FDA-cleared and address unmet needs in the delivery of radiation therapy, tumor localization and surgical guidance. i Cox CE, Russell S, Prowler V, et al. A Prospective, Single Arm, Multi-site, Clinical Evaluation of a Nonradioactive Surgical Guidance Technology for the Location of Nonpalpable Breast Lesions during Excision. Ann Surg Oncol. 2016;23(10):3168-74.


ALISO VIEJO, Calif., May 24, 2017 (GLOBE NEWSWIRE) -- Cianna Medical, Inc., the world leader in wire-free breast localization, announces that more than 125 medical centers across the U.S. have adopted the Company’s proprietary SCOUT® radar breast localization system.  SCOUT is the world’s only radar technology that has application in human tissue, and the system allows surgeons to precisely locate non-palpable breast lesions during a lumpectomy or biopsy surgery with ± 1mm of accuracy. Nationwide, community-based hospitals and leading academic cancer centers including USF Breast Health Program at the University of South Florida, Northwell Health, Houston Methodist Willowbrook Hospital and Houston Methodist The Woodlands Hospital have adopted this groundbreaking technology. “Our first priority is saving the lives of patients with cancer and, in the process, we strive to improve their radiological and surgical experiences,” said Anne M. Wallace, MD, director of the Comprehensive Breast Health Center at Moores Cancer Center at UC San Diego Health, the 100th hospital to adopt SCOUT. “With wire-free breast localization, there is a dual benefit. The surgeon can perform a more targeted operation that conserves healthy tissue while the patient experiences less discomfort and stress.” SCOUT is the world’s only non-radioactive, wire-free breast localization system. With SCOUT, the radiologist is able to place a tiny, highly sophisticated reflector at the tumor site with extreme precision. This can be done up to 30 days prior to surgery versus on the same day of surgery which is required with traditional wire localization. Instead of two procedures on the day of surgery, the patient now undergoes one, which can help make the experience significantly less stressful. During the procedure, the surgeon scans the breast using the SCOUT guide, which emits 50 million pulses per second, allowing the surgeon to “lock” in on the reflector’s precise location with ± 1mm of accuracy. This extraordinary accuracy can help surgeons provide the best possible outcomes. SCOUT has an exceptional detection range of 1mm – 50mm1, documented migration of only <1% across multiple studies1 and is 100% operating room (OR) compatible. “At Cianna Medical, we have been focused on breast conservation therapy for more than a decade. Our company is dedicated to helping reduce the anxiety and stress breast cancer treatments place on patients and their families. We do this by developing innovative technologies that improve the entire continuum of care,” said Jill Anderson, President and CEO of Cianna Medical. “Reaching adoption at more than 125 centers is a significant milestone and we are grateful for the uncompromising support of our clinical collaborators and dedicated team. We are confident that SCOUT is becoming the new standard of care and will be recognized as the breast localization technology of choice.” SCOUT was a recent category finalist in the 2016 Fierce Innovation Awards: Life Sciences Edition for outstanding technology innovation in December 2016. SCOUT also received the Scientific Impact Award at the 2016 Society of Breast Surgeons Annual Meeting for data validating its clinical utility. Earlier this year, SCOUT was also honored as a finalist in the 2017 Medical Design Excellence Awards. For more information, call 866.920.9444 or visit www.ciannamedical.com. About SCOUT® The FDA-cleared SCOUT system features a proprietary, highly sophisticated reflector that is precisely placed at the tumor site up to 30 days before a lumpectomy or surgical biopsy. During the procedure, the surgeon scans the breast using the SCOUT guide which emits 50 million pulses per second, allowing the surgeon to “lock” in on the reflector’s precise location with ± 1mm of accuracy. This higher level of localization precision allows better surgical planning that may improve cosmetic results as less tissue may need to be removed. SCOUT has an exceptional detection range of 1mm – 50mm, documented migration of <1% across multiple studies, and is OR compatible.i About Radar Technology The SCOUT system uses highly sophisticated radar technology. Radar is used when unprecedented precision is required. Applications using radar include ground penetrating radar, automobile safety systems, flight control systems and antimissile and air-defense systems. About Cianna Medical, Inc. Cianna Medical is the world leader in wire-free breast localization and has been focused on breast conservation for over 10 years. Cianna Medical develops, manufactures and markets innovative medical technologies that reduce costs, improve quality and reduce the anxiety and stress breast cancer treatments place on women and their families. Cianna Medical’s world class research, development and commercialization teams developed the world’s first non-radioactive, wire-free breast localization system and the world’s only technology that utilizes radar in tissue. Cianna Medical is focused on expanding applications that continually advance patient care. Its SCOUT and SAVI® Brachy technologies are FDA-cleared and address unmet needs in the delivery of radiation therapy, tumor localization and surgical guidance. i Cox CE, Russell S, Prowler V, et al. A Prospective, Single Arm, Multi-site, Clinical Evaluation of a Nonradioactive Surgical Guidance Technology for the Location of Nonpalpable Breast Lesions during Excision. Ann Surg Oncol. 2016;23(10):3168-74.


ALISO VIEJO, Calif., May 24, 2017 (GLOBE NEWSWIRE) -- Cianna Medical, Inc., the world leader in wire-free breast localization, announces that more than 125 medical centers across the U.S. have adopted the Company’s proprietary SCOUT® radar breast localization system.  SCOUT is the world’s only radar technology that has application in human tissue, and the system allows surgeons to precisely locate non-palpable breast lesions during a lumpectomy or biopsy surgery with ± 1mm of accuracy. Nationwide, community-based hospitals and leading academic cancer centers including USF Breast Health Program at the University of South Florida, Northwell Health, Houston Methodist Willowbrook Hospital and Houston Methodist The Woodlands Hospital have adopted this groundbreaking technology. “Our first priority is saving the lives of patients with cancer and, in the process, we strive to improve their radiological and surgical experiences,” said Anne M. Wallace, MD, director of the Comprehensive Breast Health Center at Moores Cancer Center at UC San Diego Health, the 100th hospital to adopt SCOUT. “With wire-free breast localization, there is a dual benefit. The surgeon can perform a more targeted operation that conserves healthy tissue while the patient experiences less discomfort and stress.” SCOUT is the world’s only non-radioactive, wire-free breast localization system. With SCOUT, the radiologist is able to place a tiny, highly sophisticated reflector at the tumor site with extreme precision. This can be done up to 30 days prior to surgery versus on the same day of surgery which is required with traditional wire localization. Instead of two procedures on the day of surgery, the patient now undergoes one, which can help make the experience significantly less stressful. During the procedure, the surgeon scans the breast using the SCOUT guide, which emits 50 million pulses per second, allowing the surgeon to “lock” in on the reflector’s precise location with ± 1mm of accuracy. This extraordinary accuracy can help surgeons provide the best possible outcomes. SCOUT has an exceptional detection range of 1mm – 50mm1, documented migration of only <1% across multiple studies1 and is 100% operating room (OR) compatible. “At Cianna Medical, we have been focused on breast conservation therapy for more than a decade. Our company is dedicated to helping reduce the anxiety and stress breast cancer treatments place on patients and their families. We do this by developing innovative technologies that improve the entire continuum of care,” said Jill Anderson, President and CEO of Cianna Medical. “Reaching adoption at more than 125 centers is a significant milestone and we are grateful for the uncompromising support of our clinical collaborators and dedicated team. We are confident that SCOUT is becoming the new standard of care and will be recognized as the breast localization technology of choice.” SCOUT was a recent category finalist in the 2016 Fierce Innovation Awards: Life Sciences Edition for outstanding technology innovation in December 2016. SCOUT also received the Scientific Impact Award at the 2016 Society of Breast Surgeons Annual Meeting for data validating its clinical utility. Earlier this year, SCOUT was also honored as a finalist in the 2017 Medical Design Excellence Awards. For more information, call 866.920.9444 or visit www.ciannamedical.com. About SCOUT® The FDA-cleared SCOUT system features a proprietary, highly sophisticated reflector that is precisely placed at the tumor site up to 30 days before a lumpectomy or surgical biopsy. During the procedure, the surgeon scans the breast using the SCOUT guide which emits 50 million pulses per second, allowing the surgeon to “lock” in on the reflector’s precise location with ± 1mm of accuracy. This higher level of localization precision allows better surgical planning that may improve cosmetic results as less tissue may need to be removed. SCOUT has an exceptional detection range of 1mm – 50mm, documented migration of <1% across multiple studies, and is OR compatible.i About Radar Technology The SCOUT system uses highly sophisticated radar technology. Radar is used when unprecedented precision is required. Applications using radar include ground penetrating radar, automobile safety systems, flight control systems and antimissile and air-defense systems. About Cianna Medical, Inc. Cianna Medical is the world leader in wire-free breast localization and has been focused on breast conservation for over 10 years. Cianna Medical develops, manufactures and markets innovative medical technologies that reduce costs, improve quality and reduce the anxiety and stress breast cancer treatments place on women and their families. Cianna Medical’s world class research, development and commercialization teams developed the world’s first non-radioactive, wire-free breast localization system and the world’s only technology that utilizes radar in tissue. Cianna Medical is focused on expanding applications that continually advance patient care. Its SCOUT and SAVI® Brachy technologies are FDA-cleared and address unmet needs in the delivery of radiation therapy, tumor localization and surgical guidance. i Cox CE, Russell S, Prowler V, et al. A Prospective, Single Arm, Multi-site, Clinical Evaluation of a Nonradioactive Surgical Guidance Technology for the Location of Nonpalpable Breast Lesions during Excision. Ann Surg Oncol. 2016;23(10):3168-74.


ALISO VIEJO, Calif., May 24, 2017 (GLOBE NEWSWIRE) -- Cianna Medical, Inc., the world leader in wire-free breast localization, announces that more than 125 medical centers across the U.S. have adopted the Company’s proprietary SCOUT® radar breast localization system.  SCOUT is the world’s only radar technology that has application in human tissue, and the system allows surgeons to precisely locate non-palpable breast lesions during a lumpectomy or biopsy surgery with ± 1mm of accuracy. Nationwide, community-based hospitals and leading academic cancer centers including USF Breast Health Program at the University of South Florida, Northwell Health, Houston Methodist Willowbrook Hospital and Houston Methodist The Woodlands Hospital have adopted this groundbreaking technology. “Our first priority is saving the lives of patients with cancer and, in the process, we strive to improve their radiological and surgical experiences,” said Anne M. Wallace, MD, director of the Comprehensive Breast Health Center at Moores Cancer Center at UC San Diego Health, the 100th hospital to adopt SCOUT. “With wire-free breast localization, there is a dual benefit. The surgeon can perform a more targeted operation that conserves healthy tissue while the patient experiences less discomfort and stress.” SCOUT is the world’s only non-radioactive, wire-free breast localization system. With SCOUT, the radiologist is able to place a tiny, highly sophisticated reflector at the tumor site with extreme precision. This can be done up to 30 days prior to surgery versus on the same day of surgery which is required with traditional wire localization. Instead of two procedures on the day of surgery, the patient now undergoes one, which can help make the experience significantly less stressful. During the procedure, the surgeon scans the breast using the SCOUT guide, which emits 50 million pulses per second, allowing the surgeon to “lock” in on the reflector’s precise location with ± 1mm of accuracy. This extraordinary accuracy can help surgeons provide the best possible outcomes. SCOUT has an exceptional detection range of 1mm – 50mm1, documented migration of only <1% across multiple studies1 and is 100% operating room (OR) compatible. “At Cianna Medical, we have been focused on breast conservation therapy for more than a decade. Our company is dedicated to helping reduce the anxiety and stress breast cancer treatments place on patients and their families. We do this by developing innovative technologies that improve the entire continuum of care,” said Jill Anderson, President and CEO of Cianna Medical. “Reaching adoption at more than 125 centers is a significant milestone and we are grateful for the uncompromising support of our clinical collaborators and dedicated team. We are confident that SCOUT is becoming the new standard of care and will be recognized as the breast localization technology of choice.” SCOUT was a recent category finalist in the 2016 Fierce Innovation Awards: Life Sciences Edition for outstanding technology innovation in December 2016. SCOUT also received the Scientific Impact Award at the 2016 Society of Breast Surgeons Annual Meeting for data validating its clinical utility. Earlier this year, SCOUT was also honored as a finalist in the 2017 Medical Design Excellence Awards. For more information, call 866.920.9444 or visit www.ciannamedical.com. About SCOUT® The FDA-cleared SCOUT system features a proprietary, highly sophisticated reflector that is precisely placed at the tumor site up to 30 days before a lumpectomy or surgical biopsy. During the procedure, the surgeon scans the breast using the SCOUT guide which emits 50 million pulses per second, allowing the surgeon to “lock” in on the reflector’s precise location with ± 1mm of accuracy. This higher level of localization precision allows better surgical planning that may improve cosmetic results as less tissue may need to be removed. SCOUT has an exceptional detection range of 1mm – 50mm, documented migration of <1% across multiple studies, and is OR compatible.i About Radar Technology The SCOUT system uses highly sophisticated radar technology. Radar is used when unprecedented precision is required. Applications using radar include ground penetrating radar, automobile safety systems, flight control systems and antimissile and air-defense systems. About Cianna Medical, Inc. Cianna Medical is the world leader in wire-free breast localization and has been focused on breast conservation for over 10 years. Cianna Medical develops, manufactures and markets innovative medical technologies that reduce costs, improve quality and reduce the anxiety and stress breast cancer treatments place on women and their families. Cianna Medical’s world class research, development and commercialization teams developed the world’s first non-radioactive, wire-free breast localization system and the world’s only technology that utilizes radar in tissue. Cianna Medical is focused on expanding applications that continually advance patient care. Its SCOUT and SAVI® Brachy technologies are FDA-cleared and address unmet needs in the delivery of radiation therapy, tumor localization and surgical guidance. i Cox CE, Russell S, Prowler V, et al. A Prospective, Single Arm, Multi-site, Clinical Evaluation of a Nonradioactive Surgical Guidance Technology for the Location of Nonpalpable Breast Lesions during Excision. Ann Surg Oncol. 2016;23(10):3168-74.


Chen X.,Comprehensive Breast Health Center | Fei X.,Shanghai JiaoTong University | Fu C.,Siemens AG | Yan X.,Siemens AG | Shen K.,Comprehensive Breast Health Center
Radiology | Year: 2015

Purpose: To assess diagnostic accuracy with diffusion kurtosis imaging (DKI) in patients with breast lesions and to evaluate the potential association between DKI-derived parameters and breast cancer clinical-pathologic factors. Materials and Methods: Institutional review board approval and written informed consent were obtained. Data from 97 patients (mean age 6 standard deviation, 45.7 years 6 13.1; range, 19-70 years) with 98 lesions (57 malignant and 41 benign) who were treated between January 2014 and April 2014 were retrospectively analyzed. DKI (with b values of 0-2800 sec/mm2) and conventional diffusion-weighted imaging data were acquired. Kurtosis and diffusion coefficients from DKI and apparent diffusion coefficients from diffusion-weighted imaging were measured by two radiologists. Student t test, Wilcoxon signed-rank test, Jonckheere-Terpstra test, receiver operating characteristic curves, and Spearman correlation were used for statistical analysis. Results: Kurtosis coefficients were significantly higher in the malignant lesions than in the benign lesions (1.05 6 0.22 vs 0.65 6 0.11, respectively; P , .0001). Diffusivity and apparent diffusion coefficients in the malignant lesions were significantly lower than those in the benign lesions (1.13 6 0.27 vs 1.97 6 0.33 and 1.02 6 0.18 vs 1.48 6 0.33, respectively; P , .0001). Significantly higher specificity for differentiation of malignant from benign lesions was shown with the use of kurtosis and diffusivity coefficients than with the use of apparent diffusion coefficients (83% [34 of 41] and 83% [34 of 41] vs 76% [31 of 41], respectively; P , .0001) with equal sensitivity (95% [54 of 57]). In patients with invasive breast cancer, kurtosis was positively correlated with tumor histologic grade (r = 0.75) and expression of the Ki-67 protein (r = 0.55). Diffusivity was negatively correlated with tumor histologic grades (r = 20.44) and Ki-67 expression (r = 20.46). Conclusion: DKI showed higher specificity than did conventional diffusion-weighted imaging for assessment of benign and malignant breast lesions. Patients with grade 3 breast cancer or tumors with high expression of Ki-67 were associated with higher kurtosis and lower diffusivity coefficients; however, this association must be confirmed in prospective studies. © RSNA, 2015.

Loading Comprehensive Breast Health Center collaborators
Loading Comprehensive Breast Health Center collaborators